Baughman Derek J, Watson Crista M, Beich Jonathan W, Herboso May N Joresa, Cuttie Liana K, Marlyne Ari-Beth C
Medical Director-Primary Care, Barksdale AFB, 2nd Medical Group, Barksdale AFB, LA 71110, USA.
Physician Assistant-Family Health, Barksdale AFB, 2nd Medical Group, Barksdale AFB, LA 71110, USA.
Mil Med. 2024 May 18;189(5-6):e1343-e1352. doi: 10.1093/milmed/usad403.
In addition to the higher burden of mental health disease in the military, there is a compounding antecedent association between behavioral health comorbidities and the treatment of attention-deficit/hyperactivity disorder (ADHD) in this population. Despite the low prevalence of new-onset ADHD in adults globally, the rate of stimulant (i.e., amphetamines) prescription is increasing. Stimulants can exacerbate mental health disease (often masquerading as ADHD symptomatology), precluding optimal treatment of the underlying etiology and imposing unnecessary dangerous side effects. This study aimed to evaluate the long-term safety and efficacy of stimulants for managing adult ADHD.
A nine-member multidisciplinary team reviewed a PubMed search with the terms "adult," "ADHD," and "stimulant." Targeted PubMed and Google Scholar searches for "adult ADHD" paired with Food and Drug Administration -approved ADHD medications and Google Scholar literature using forward and reverse snowballing methods were performed for high-quality studies focusing on long-term treatment in ADHD. An evidence table and clinical algorithm were developed from the review.
Of the 1,039 results, 50 articles were fully reviewed, consisting of 21 descriptive and experimental studies, 18 observational, and 11 systematic reviews and meta-analyses. Illustrative cases within the structured discussion of the results highlighted ADHD and psychiatric comorbidities, risks, harms, and benefits of stimulant use, medication mechanisms of action, and limitations of the current evidence.
The dearth of high-quality studies on long-term ADHD management in adults fails to establish a causal relationship between stimulant use and physiological harm. Despite mixed evidence supporting the benefit of stimulants, there is clear evidence regarding the risk of harm. The serious risks of stimulants include arrhythmias, myocardial infarction, stroke/transient ischemic attack, sudden death, psychosis, and worsening of behavioral health disease. Additionally, there is a possible long-term risk of harm due to chronic sympathetic load (i.e., cardiovascular system remodeling). Stimulants pose a greater risk for addiction and abuse compared to other evidence-based nonstimulant medications that have similar effectiveness. Both stimulants and nonstimulants might promote favorable neuroanatomical changes for long-term improvement of ADHD symptoms, but nonstimulants (atomoxetine) have the pharmacological advantage of also mitigating the effects of sympathetic load (sympatholysis) and anxiety (anxiolysis). Given the physiological uncertainty of extended stimulant use for adults, especially older adults with vulnerable cardiovascular systems, clinicians should proceed cautiously when considering initiating or sustaining stimulant therapy. For long-term treatment of ADHD in adults, clinicians should consider nonstimulant alternatives (including behavioral therapy) due to the comparatively lower side effect risk and the possible additional benefit in patients with behavioral health comorbidities.
Long-term safety of stimulant use for adults with ADHD is uncertain, as existing studies are limited in quality and duration. This is particularly important for military populations with higher rates of mental health conditions. Managing ADHD and related conditions requires prioritizing cardiovascular safety, especially for older adults. Nonstimulant options can be helpful, especially in comorbid psychiatric disease. Before treating ADHD, ruling out and controlling other behavioral health conditions is essential to avoid masking or worsening underlying issues and reducing unnecessary medication side effects.
除了军队中精神疾病负担较重外,该人群中行为健康合并症与注意力缺陷多动障碍(ADHD)的治疗之间还存在复杂的先行关联。尽管全球成人新发ADHD的患病率较低,但兴奋剂(即苯丙胺类)的处方率却在上升。兴奋剂会加重精神疾病(常表现为ADHD症状),妨碍对潜在病因的最佳治疗,并带来不必要的危险副作用。本研究旨在评估兴奋剂治疗成人ADHD的长期安全性和有效性。
一个由九名成员组成的多学科团队对PubMed上以“成人”“ADHD”和“兴奋剂”为关键词的搜索结果进行了审查。针对PubMed和谷歌学术进行了有针对性的搜索,搜索词为“成人ADHD”,并与美国食品药品监督管理局批准的ADHD药物配对,同时利用向前和反向滚雪球法在谷歌学术文献中搜索聚焦于ADHD长期治疗的高质量研究。通过审查制定了证据表和临床算法。
在1039条结果中,对50篇文章进行了全面审查,其中包括21项描述性和实验性研究、18项观察性研究以及11项系统评价和荟萃分析。结果的结构化讨论中的示例病例突出了ADHD和精神合并症、使用兴奋剂的风险、危害和益处、药物作用机制以及当前证据的局限性。
关于成人ADHD长期管理的高质量研究匮乏,未能确立使用兴奋剂与生理伤害之间的因果关系。尽管有混合证据支持兴奋剂的益处,但关于危害风险的证据确凿。兴奋剂的严重风险包括心律失常、心肌梗死、中风/短暂性脑缺血发作、猝死、精神病以及行为健康疾病的恶化。此外,由于慢性交感神经负荷(即心血管系统重塑),可能存在长期危害风险。与其他具有相似疗效的循证非兴奋剂药物相比,兴奋剂成瘾和滥用的风险更大。兴奋剂和非兴奋剂都可能促进有利于长期改善ADHD症状的神经解剖学变化,但非兴奋剂(托莫西汀)具有减轻交感神经负荷(交感神经阻滞)和焦虑(抗焦虑)作用的药理学优势。鉴于成人长期使用兴奋剂存在生理不确定性,尤其是心血管系统脆弱的老年人,临床医生在考虑启动或维持兴奋剂治疗时应谨慎行事。对于成人ADHD的长期治疗,临床医生应考虑使用非兴奋剂替代方案(包括行为疗法),因为其副作用风险相对较低,且对有行为健康合并症的患者可能有额外益处。
成人使用兴奋剂的长期安全性尚不确定,因为现有研究在质量和持续时间方面存在局限性。这对精神健康状况发生率较高的军人尤为重要。管理ADHD及相关病症需要优先考虑心血管安全性,尤其是对老年人。非兴奋剂选择可能会有所帮助,特别是在合并精神疾病的情况下。在治疗ADHD之前,排除和控制其他行为健康状况对于避免掩盖或加重潜在问题以及减少不必要的药物副作用至关重要。